Rotavirus vaccine effectiveness in low-income settings: An evaluation of the test-negative design
MetadataShow full item record
AbstractBackground The test-negative design (TND), an epidemiologic method currently used to measure rotavirus vaccine (RV) effectiveness, compares the vaccination status of rotavirus-positive cases and rotavirus-negative controls meeting a pre-defined case definition for acute gastroenteritis. Despite the use of this study design in low-income settings, the TND has not been evaluated to measure rotavirus vaccine effectiveness. Methods This study builds upon prior methods to evaluate the use of the TND for influenza vaccine using a randomized controlled clinical trial database. Test-negative vaccine effectiveness (VE-TND) estimates were derived from three large randomized placebo-controlled trials (RCTs) of monovalent (RV1) and pentavalent (RV5) rotavirus vaccines in sub-Saharan Africa and Asia. Derived VE-TND estimates were compared to the original RCT vaccine efficacy estimates (VE-RCTs). The core assumption of the TND (i.e., rotavirus vaccine has no effect on rotavirus-negative diarrhea) was also assessed. Results TND vaccine effectiveness estimates were nearly equivalent to original RCT vaccine efficacy estimates. Neither RV had a substantial effect on rotavirus-negative diarrhea. Conclusions This study supports the TND as an appropriate epidemiologic study design to measure rotavirus vaccine effectiveness in low-income settings. Copyright 2016 The Author(s)
SponsorsThis publication is based on research funded in part by the Bill & Melinda Gates Foundation [ OPP1068644 ] and the National Institutes of Health [ NIH/NIAID MERIT R37 AI032042 ].
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84999767800&doi=10.1016%2fj.vaccine.2016.10.077&partnerID=40&md5=1200c4ba0b085000ff345910bee17ceb; http://hdl.handle.net/10713/11327
- Effectiveness of Pentavalent Rotavirus Vaccine Under Conditions of Routine Use in Rwanda.
- Authors: Tate JE, Ngabo F, Donnen P, Gatera M, Uwimana J, Rugambwa C, Mwenda JM, Parashar UD
- Issue date: 2016 May 1
- Effectiveness of monovalent rotavirus vaccine in a high-income, predominant-use setting.
- Authors: Doll MK, Buckeridge DL, Morrison KT, Gagneur A, Tapiero B, Charest H, Quach C
- Issue date: 2015 Dec 16
- Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa.
- Authors: Tapia MD, Armah G, Breiman RF, Dallas MJ, Lewis KD, Sow SO, Rivers SB, Levine MM, Laserson KF, Feikin DR, Victor JC, Ciarlet M, Neuzil KM, Steele AD
- Issue date: 2012 Apr 27
- Long-term Consistency in Rotavirus Vaccine Protection: RV5 and RV1 Vaccine Effectiveness in US Children, 2012-2013.
- Authors: Payne DC, Selvarangan R, Azimi PH, Boom JA, Englund JA, Staat MA, Halasa NB, Weinberg GA, Szilagyi PG, Chappell J, McNeal M, Klein EJ, Sahni LC, Johnston SH, Harrison CJ, Baker CJ, Bernstein DI, Moffatt ME, Tate JE, Mijatovic-Rustempasic S, Esona MD, Wikswo ME, Curns AT, Sulemana I, Bowen MD, Gentsch JR, Parashar UD
- Issue date: 2015 Dec 15
- Real-World Effectiveness of Pentavalent Rotavirus Vaccine Among Bedouin and Jewish Children in Southern Israel.
- Authors: Leshem E, Givon-Lavi N, Tate JE, Greenberg D, Parashar UD, Dagan R
- Issue date: 2016 May 1